Zweig DiMenna Associates LLC purchased a new position in Myriad Genetics, Inc. (NASDAQ:MYGN) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 8,600 shares of the company’s stock, valued at approximately $311,000.
A number of other hedge funds and other institutional investors also recently bought and sold shares of MYGN. BlackRock Inc. raised its holdings in Myriad Genetics by 168,335.7% during the 1st quarter. BlackRock Inc. now owns 9,541,884 shares of the company’s stock worth $183,203,000 after buying an additional 9,536,219 shares during the period. Thrivent Financial For Lutherans raised its holdings in Myriad Genetics by 7,026.7% during the 2nd quarter. Thrivent Financial For Lutherans now owns 2,742,340 shares of the company’s stock worth $70,862,000 after buying an additional 2,703,860 shares during the period. Vanguard Group Inc. raised its holdings in Myriad Genetics by 16.8% during the 1st quarter. Vanguard Group Inc. now owns 6,251,030 shares of the company’s stock worth $120,020,000 after buying an additional 897,287 shares during the period. Dimensional Fund Advisors LP raised its holdings in Myriad Genetics by 29.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 3,430,216 shares of the company’s stock worth $88,636,000 after buying an additional 787,396 shares during the period. Finally, PDT Partners LLC acquired a new stake in Myriad Genetics during the 2nd quarter worth about $8,481,000.
WARNING: This article was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://sportsperspectives.com/2017/11/14/zweig-dimenna-associates-llc-invests-311000-in-myriad-genetics-inc-mygn-stock.html.
Shares of Myriad Genetics, Inc. (NASDAQ MYGN) opened at $32.47 on Tuesday. The company has a market capitalization of $2,184.55, a P/E ratio of 28.94, a P/E/G ratio of 2.02 and a beta of 0.24. Myriad Genetics, Inc. has a 12 month low of $15.15 and a 12 month high of $37.30. The company has a quick ratio of 2.06, a current ratio of 2.34 and a debt-to-equity ratio of 0.09.
Myriad Genetics (NASDAQ:MYGN) last announced its quarterly earnings results on Tuesday, November 7th. The company reported $0.26 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.21 by $0.05. The business had revenue of $190.20 million during the quarter, compared to analysts’ expectations of $183.52 million. Myriad Genetics had a return on equity of 9.54% and a net margin of 13.28%. The firm’s quarterly revenue was up 7.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.23 EPS. research analysts expect that Myriad Genetics, Inc. will post 1.04 earnings per share for the current year.
Several analysts have issued reports on MYGN shares. BidaskClub upgraded Myriad Genetics from a “hold” rating to a “buy” rating in a report on Saturday, August 12th. Zacks Investment Research upgraded Myriad Genetics from a “hold” rating to a “buy” rating and set a $28.00 target price on the stock in a report on Monday, July 17th. ValuEngine upgraded Myriad Genetics from a “hold” rating to a “buy” rating in a report on Friday. Barclays PLC dropped their target price on Myriad Genetics from $28.00 to $26.00 and set an “equal weight” rating on the stock in a report on Wednesday, August 9th. Finally, Cowen and Company reiterated a “hold” rating and issued a $25.00 target price on shares of Myriad Genetics in a report on Sunday, September 17th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $28.10.
In related news, Director John T. Henderson sold 30,000 shares of the business’s stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $30.30, for a total value of $909,000.00. Following the completion of the sale, the director now owns 52,524 shares of the company’s stock, valued at approximately $1,591,477.20. The sale was disclosed in a document filed with the SEC, which is available at this link. Insiders own 6.70% of the company’s stock.
Myriad Genetics Company Profile
Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.
Want to see what other hedge funds are holding MYGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myriad Genetics, Inc. (NASDAQ:MYGN).
Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.